Enbrel To Cut Into Remicade’s Medicare Monopoly Via Part D, Amgen Says
Executive Summary
Amgen sees the advent of Part D as an opportunity for Enbrel to capture some of the Medicare TNF inhibitor rheumatoid arthritis market share currently held byJohnson & Johnson's Remicade
You may also be interested in...
Amgen Struggles To Spark Enbrel Growth, Faces Increased Competition
Amgen's strategies for reviving growth in Enbrel (etanercept) are not producing the anticipated results, as the TNF inhibitor has delivered lackluster sales for several consecutive quarters
Amgen Struggles To Spark Enbrel Growth, Faces Increased Competition
Amgen's strategies for reviving growth in Enbrel (etanercept) are not producing the anticipated results, as the TNF inhibitor has delivered lackluster sales for several consecutive quarters
Biologics Under Part D: Coinsurance, Cost Containment And Coverage Overlap
Coinsurance appears to be the preferred cost-sharing method for biologics in Medicare Part D plans, according to an analysis of plan formularies by "The Pink Sheet."